19
Participants
Start Date
May 31, 2012
Primary Completion Date
July 23, 2014
Study Completion Date
July 23, 2014
Dasatinib
Tablet, oral, 140 mg, once daily until unacceptable toxicity or disease progression
Local Institution, Taipei
Memorial Sloan Kettering Cancer Center, New York
Memorial Sloan Kettering Nassau, New York
Local Institution, Barretos
H. Lee Moffitt Cancer & Research Institute, Tampa
Local Institution, Cologne
Local Institution, Cologne
Local Institution, Frankfurt
Local Institution, Heidelberg
Local Institution, Heidelberg
Local Institution, Barretos
Local Institution, S?o Paulo
Local Institution, São Paulo
The Ottawa Hospital Cancer Centre, Ottawa
Local Institution, Gdansk
Local Institution, Lodz
Local Institution, Warsaw
Local Institution, Cambridge
Local Institution, Cambridge
Local Institution, London
Local Institution, Manchester
Local Institution, Gwent
Local Institution, Edinburgh
Local Institution, Sutton
Lead Sponsor
Bristol-Myers Squibb
INDUSTRY